ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Company Country Ticker View
H. Lundbeck A Logo
Develops and commercializes innovative therapeutics for brain diseases globally.
Denmark HLUN
Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.
South Korea 145020
Human Stem Cells Institute PJSC Logo
A biotech investor developing gene therapy, regenerative medicine, and genetic services.
Russian Federation ISKJ
HUMASIS CO., LTD. Logo
Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.
South Korea 205470
Humedix Co., Ltd. Logo
Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.
South Korea 200670
HUONS CO., LTD. Logo
Global healthcare company providing pharmaceuticals, medical devices, and wellness products.
South Korea 243070
Huons Global Co., Ltd. Logo
Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.
South Korea 084110
Hong Kong N/A
HWAIL PHARM. CO., LTD Logo
Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.
South Korea 061250
Hyloris Pharmaceuticals SA Logo
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
Belgium HYL

Talk to a Data Expert

Have a question? We'll get back to you promptly.